Graft-versus-tumor effect in autologous setting: fact or fallacy?
1/5 보강
Autologous hematopoietic cell transplantation (AHCT) is usually considered a single high-dose therapy intending to eradicate existing malignant cells from the patient and enabling both hematologic and
APA
Partanen A, Kinnunen T, Jantunen E (2025). Graft-versus-tumor effect in autologous setting: fact or fallacy?. Leukemia & lymphoma, 66(13), 2388-2396. https://doi.org/10.1080/10428194.2025.2547986
MLA
Partanen A, et al.. "Graft-versus-tumor effect in autologous setting: fact or fallacy?." Leukemia & lymphoma, vol. 66, no. 13, 2025, pp. 2388-2396.
PMID
40840916 ↗
Abstract 한글 요약
Autologous hematopoietic cell transplantation (AHCT) is usually considered a single high-dose therapy intending to eradicate existing malignant cells from the patient and enabling both hematologic and immune recovery after the graft infusion. In addition to tumor biology and disease status, also the immunologic status of the patient and several factors affecting graft cellular content are crucial for posttransplant outcomes. There is evidence for an immunotherapeutic role of immune effector cells within infused grafts and of importance of immune recovery post-transplant. Here we present the pros and cons of this autograft-versus-tumor effect in myeloma and non-Hodgkin lymphoma, the two most common current indications for AHCT. In addition, we discuss ways to potentially improve current treatment results by enhancing the immunotherapeutic effect of AHCT.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Transplantation
- Autologous
- Hematopoietic Stem Cell Transplantation
- Graft vs Tumor Effect
- Multiple Myeloma
- Lymphoma
- Non-Hodgkin
- Graft vs Host Disease
- Treatment Outcome
- Autologous hematopoietic cell transplantation
- graft-versus-tumor effect
- immune recovery
- multiple myeloma
- non-Hodgkin lymphoma
- outcome
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.